Translational Autoimmunity, Volume 6

Advances in Autoimmune Rheumatic Diseases

1st Edition - February 20, 2023
Editor: Nima Rezaei
Language: English
Paperback ISBN:
9 7 8 - 0 - 3 2 3 - 8 5 8 3 1 - 1
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 8 4 5 4 - 6

Translational Autoimmunity: Advances in Autoimmune Rheumatic Diseases, Volume Six addresses autoimmune diseases classified under the category of rheumatic diseases. Rheumatic… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Translational Autoimmunity: Advances in Autoimmune Rheumatic Diseases, Volume Six addresses autoimmune diseases classified under the category of rheumatic diseases. Rheumatic diseases are heterogeneous groups of disorders in which inflammation affects not only joints, but also tendons, ligaments and bones. This updated release focuses on immunopathogenesis and clinical and laboratory details of rheumatic diseases, including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, osteoarthritis and Sjogren’s syndrome, and will be of interest to researchers, students and clinicians interested in autoimmune diseases, especially rheumatic diseases.

From an introduction to rheumatic diseases to diagnostic laboratory tests, and from the microbiota-immunity to cell-based therapies, the bench to bedside approach to rheumatic diseases is the main subject of discussion in this comprehensive resource.

Cover
Title page
Table of Contents
Copyright
Dedication
Contributors
Preface
Series editor’s biography
Acknowledgment
Abbreviations
Chapter 1: Introduction on autoimmune rheumatic diseases
Abstract
1: Introduction
2: ARD through the history
3: Diagnosis of ARD
4: Treatment of ARD
5: Conclusion
References
Chapter 2: Bone Health in autoimmune inflammatory rheumatic diseases
Abstract
1: Introduction
2: Prevalence of bone health impairment in AIIRD
3: Risk factors for bone loss in AIIRD
4: Pathophysiology of bone loss in AIIRD
5: Evaluation and management of bone loss/osteoporosis in patients with AIIRD
6: Conclusion
References
Chapter 3: Rheumatic diseases: From bench to bedside
Abstract
1: Introduction
2: Pathogenesis of autoimmunity in rheumatic diseases (AIRDs)
3: Comparisons of the immunopathogenesis in various autoimmune rheumatic diseases
4: The clinical implications of the immunopathogenesis of autoimmunity
5: Conclusion
References
Chapter 4: Rheumatic fever: From pathogenesis to vaccine perspectives
Abstract
1: Introduction
2: Diagnosis of acute rheumatic fever
3: Major manifestation
4: Minor manifestations
5: Treatment
6: Conclusion
References
Chapter 5: Changes in future rheumatoid arthritis treatment in the light of Epstein-Barr virus infection
Abstract
1: Introduction
2: Epstein-Barr virus
3: Epstein-Barr virus infections
4: Associations between Epstein-Barr virus and rheumatoid arthritis disease
5: Current and future treatment of rheumatoid arthritis disease
6: Conclusion
References
Chapter 6: Rheumatic diseases: The microbiota-immunity axis in development and treatment
Abstract
1: Introduction
2: The microbiota and the immune system crosstalk
3: Microbiota and autoimmune rheumatic diseases
4: Microbiota shaping as a potential therapeutic target
5: Conclusion
References
Chapter 7: The diagnostic laboratory tests in rheumatic diseases
Abstract
1: Introduction
2: Acute-phase reactants
3: Laboratory tests in rheumatoid arthritis
4: Laboratory tests in spondyloarthritis
5: Laboratory tests in autoimmune connective tissue diseases
6: Laboratory tests in vasculitis
7: Laboratory tests in infectious arthritis
8: Laboratory tests in microcrystalline arthritis
9: Laboratory tests in osteoporosis
10: Laboratory tests in periodic fevers
11: Appendix: Analysis of the synovial fluid
12: Conclusion
References
Chapter 8: Autoantibody profiling in autoimmune rheumatic diseases: How research may translate into clinical practice
Abstract
1: Introduction
2: The clinical rationale of autoantibody profiling
3: Proteomic technology for multiautoantibody profiling
4: Autoantibody profiling in autoimmune rheumatic diseases
5: Antibody profiling in rheumatoid arthritis
6: Autoantibody profiling in autoimmune organ-specific diseases
7: Analytical challenges of multiplex technology
8: Conclusion
References
Chapter 9: Air pollution and rheumatoid arthritis: Current knowledge and state of the art
Abstract
Acknowledgments
1: Introduction
2: Overview of air pollution and its health effects
3: Studies linking air pollution with rheumatoid arthritis
4: Mechanisms potentially linking air pollution with rheumatoid arthritis
5: Future directions
6: Conclusion
References
Chapter 10: Advanced therapies in rheumatoid arthritis
Abstract
1: Introduction
2: Etiology and pathogenesis
3: Presentation
4: Articular features of RA
5: Extra-articular features of RA
6: Diagnosis
7: Management of the disease
8: EULAR treatment recommendations
9: Horizon scanning for new agents
10: Conclusion
References
Chapter 11: A tolerogenic dendritic cell–based therapy targeting heat shock protein–specific regulatory T cells in rheumatoid arthritis
Abstract
1: Introduction
2: Heat shock proteins
3: Preclinical and clinical studies of HSP-induced tolerance
4: Preclinical studies with tolDCs
5: Toward HSP-loaded tolDCs as a therapy for RA
6: Conclusion
References
Chapter 12: T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis
Abstract
1: Introduction
2: Epidemiology
3: Pathogenesis
4: Diagnosis
5: Clinical manifestations
6: Differential diagnosis
7: Treatment
8: Conclusion
References
Chapter 13: Biomaterials as tools for re-balancing skewed immunity in rheumatoid arthritis
Abstract
1: Introduction
2: Biomaterials-based strategies for rebalancing the skewed RA immunity
3: Conclusion
References
Chapter 14: Immunopathogenesis of systemic lupus erythematosus
Abstract
1: Introduction
2: Genetic factors in SLE
3: Epigenetic mechanisms in SLE
4: Environmental factors and gender in SLE
5: Apoptosis and SLE
6: The complement system and SLE
7: Toll-like receptors and SLE
8: Innate and adaptive immunity
9: Tissue inflammation and clinical manifestations (organ-specific disease features)
10: Treatment
11: Conclusion
References
Chapter 15: Challenges in systemic lupus erythematosus: From bench to bedside
Abstract
Acknowledgments
1: Introduction
2: Pathogenesis
3: Diagnosis
4: Classification criteria
5: SLE phenotypes and key disease biomarkers
6: Management
7: Management of cardiovascular disease risk
8: Management of lupus nephritis (LN)
9: Management of refractory SLE with a focus on phase 2/3 clinical trials
10: Conclusion
References
Chapter 16: Therapeutic potential of the current options in treating systemic lupus erythematosus: Challenges and prospective
Abstract
1: Introduction
2: SLE progression and factors affecting it
3: Therapeutic options for SLE
4: Current strategies to combat ADS
5: Conclusion
References
Chapter 17: The pathology and potential clinical applicability of interfering T cells in systemic lupus erythematosus
Abstract
1: Introduction
2: Pivotal immunologic players in SLE pathophysiology
3: Physiology and anatomy of T cells
4: Current and evaluated therapies of SLE that manipulate T-cell physiology
5: Phenotypic and functional change of T-cell subsets after B-cell depletion
6: Conclusion
References
Chapter 18: Rheumatic chorea
Abstract
1: Introduction
2: Pathophysiology
3: Clinical features
4: Treatment options
5: Conclusion
References
Chapter 19: Evaluation and surgical management of the rheumatoid foot and ankle
Abstract
1: Introduction
2: History and physical exam
3: Preoperative considerations
4: Vascular evaluation in the rheumatoid patient
5: Preoperative testing
6: Preoperative medication considerations
7: Venous thromboembolism prophylaxis
8: Foot and ankle manifestations of rheumatoid arthritis
9: Extraarticular and soft-tissue disorders
10: Pathomechanics
11: Forefoot reconstruction
12: Midfoot
13: Rearfoot
14: Ankle
15: Conclusion
References
Further reading
Chapter 20: Immunopathogenesis and treatment of scleroderma
Abstract
Acknowledgment
1: Introduction
2: Pathogenesis
3: Treatment
4: Conclusion
References
Chapter 21: Skin manifestations and autoimmune disturbances in dermatomyositis
Abstract
1: Introduction
2: Cutaneous manifestations of DM correlate with specific autoantibodies
3: Myositis-specific autoantibodies in a new classification system
4: Conclusion
References
Chapter 22: T cells in the pathogenesis of systemic sclerosis
Abstract
1: Introduction
2: Pathogenesis of systemic sclerosis
3: T cells: A brief overview
4: T cells in systemic sclerosis
5: Th2/Th1 balance in systemic sclerosis
6: Th17 cells
7: Regulatory T cells (Tregs) and Tregs/Th17 balance
8: Tfh cells
9: Other Th subsets
10: Unconventional T cells
11: Angiogenic T cells
12: T cells and vasculopathy
13: Lessons from animal models of scleroderma
14: Immunotherapy and future prospects
15: Conclusion
References
Chapter 23: Etiopathogenesis of Behçet’s syndrome: The role of infectious, genetic, and immunological environmental factors
Abstract
1: Introduction
2: Microbial etiology
3: Genetic etiology
4: Epigenetic contribution
5: Immunological etiology
6: Additional triggering factors
7: Conclusion
References
Chapter 24: Interleukin-1 family in Behçet’s disease: Inflammatory and antiinflammatory mediators
Abstract
1: Introduction
2: The biological characteristics of IL-1 family cytokines
3: The association of IL-1 family genes and BD
4: Expression and function of IL-1 family cytokines in BD
5: Clinical application and participation of IL-1 family cytokines in BD
6: Conclusion
References
Chapter 25: Salivary gland regeneration and repair in Sjögren’s syndrome
Abstract
1: Introduction
2: Salivary glands in Sjögren’s syndrome
3: Regenerative medicine
4: Regeneration of salivary glands
5: Conclusion
References
Chapter 26: Regulation of bone and joint inflammation by type 2 innate lymphoid cells
Abstract
1: Introduction
2: Rheumatoid arthritis and T cell
3: Rheumatoid arthritis and ILC
4: Spondyloarthritis and ILCs
5: Role of ILC2 on the initiation phase of arthritis
6: Bone homeostasis and cytokines mediated by T cell
7: Bone homeostasis and ILC
8: Conclusion
References
Chapter 27: Arboviruses (Alphavirus) related to autoimmune rheumatic diseases: Triggers and possible therapeutic interventions
Abstract
1: Introduction
2: Chikungunya virus (CHIKV)
3: O’nyong-nyong virus (ONNV)
4: Ross River virus (RRV)
5: Barmah Forest virus (BFV)
6: Mayaro virus (MAYV)
7: Sindbis virus (SINV)
8: Interface of possible treatments for alphaviruses in rheumatoid arthritis
9: Conclusion
References
Chapter 28: Rheumatologic manifestations of autoinflammatory diseases
Abstract
1: Introduction
2: Familial Mediterranean fever (FMF)
3: Mevalonate kinase deficiency (MKD)
4: Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS)
5: Cryopyrin-associated periodic syndromes (CAPS)
6: Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome
7: Conclusion
References
Index

Purchase options

Save 50% on book bundles

Institutional subscription on ScienceDirect

Nima Rezaei